Anti-viral drug therapy market comprises of sales of branded & generic anti-viral drugs and related services by entities that manufacture the branded or generic anti-viral drugs for treating microbial infections. Anti-viral drug therapy industry includes several establishments that manufacture anti-viral drugs, which are used to treat diseases caused by viral infections. Examples of antiviral drugs include cidofovir, amantadine, zanamivir, idoxuridine, famiciclovir, tenofovir, adefovir and ribavirin.
According to study, “Anti-Viral Drug Therapy Global Market Report 2020-30: Covid 19 Implications and Growth” the key companies operating in the global anti-viral drug therapy market are Johnson & Johnson, Gilead Sciences Inc, Merck & Co., Inc, GlaxoSmithKline plc., AbbVie Inc., Aurobindo Pharma, Bristol-Myers-Squibb, Dr. Reddy’s Laboratories Ltd, Boehringer Ingelheim, Hanmi Pharmaceutical, Cipla Inc, Daewoong Pharmaceutical Co. Ltd, KYORIN Holdings, Inc., Fosun Pharma, Jiangsu Hengrui Medicine Co., Ltd., Shanghai Pharmaceuticals, Yangtze River Pharmaceutical Group, Xian-Janssen Pharmaceutical Ltd, Harbin Pharmaceutical Group, Guangzhou Pharmaceutical Company Limited, Xian-Janssen Pharmaceutical Ltd, Harbin Pharmaceutical Group, Shanghai Acebright Pharmaceuticals Group Co., Ltd., Sinopharm Group, Lupin Limited, CSPC Pharmaceutical, China Meheco, Sun Pharma, Zydus Cadila, Divis Laboratories, Intas Pharmaceuticals, Alkem Laboratories, Strides Pharma, Takeda Pharmaceutical Company, Glenmark Pharmaceuticals, Nichi-Iko Pharmaceutical Co., Ltd., Otsuka Pharmaceutical, Chugai Pharmaceutical Co., Daiichi Sankyo, Mitsubishi Tanabe Pharma, Astellas Pharma, Shionogi Co. Ltd., Sumitomo Dainippon Pharma, Teva UK Limited, Eisai, AstraZeneca, Vectura Group, Abbott Laboratories, Roche Holding AG, Novartis AG, Hikma Pharmaceuticals, Pfizer, Pharmasyntez, Sanofi, ChemRar Group, R-Pharm, Pharmstandard, ChemRar Group, Alium, BioCryst Pharmaceuticals Inc., Servier, Novo Nordisk, Emergent BioSolutions, Selva Therapeutics, EMS Pharma, Apotex, Eurofarma, Cristalia, União Quimica, Gulf Pharmaceutical Industries, Libbs, Medical Appliances Corporation (SPIMACO), Saudi Pharmaceutical Industries, BMS, Mylan Laboratories, Ascedis Health. Key companies are increasingly focusing on development & launching of combination drug therapy to treat HIV and other viral infections. Combination therapies involve the formulation of different drugs to treat the different diseases.
Based on drug class, anti-viral drug therapy market is segmented as Protease Inhibitors, DNA (Nucleotide) Polymerase Inhibitors, Neuraminidase Inhibitors, Reverse Transcriptase Inhibitors and others. In addition, based on application, market is segmented as herpes, HIV, influenza, hepatitis and others.
The anti-viral drug therapy market is driven by rise in number of COVID-19 cases, followed by growth in development of drug discovery procedures. However, increase in pricing pressures and patent expiration may impact the market. Moreover, growth in development of advanced technologies is a key opportunity for market.
Based on geography, the North-American region dominates the global anti-viral drug therapy market owing to increase in virus life-threatening diseases like bird flu and strong development pipeline in the region. The Asian-Pacific and European regions are estimated to witness higher growth rate due to rise in healthcare expenditure coupled with growth in research & development (R&D) investments over the forecast period. It is anticipated that future of the global market as a result of increase in incidence rates of viral infections particularly HIV during the forecast period. It is also anticipated that global anti-viral drug therapy market will be reached at US $62.6 billion at a CAGR of 4.6% by 2023.
For More Information, Click on the Link Below:-
Ankur Gupta, Head Marketing & Communications